In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats

被引：41

作者：

Hatanaka, Toshiki ^{[1
]}

Ukai, Masashi ^{[1
]}

Watanabe, Mai ^{[1
]}

Someya, Akiyoshi ^{[1
]}

Ohtake, Akiyoshi ^{[1
]}

Suzuki, Masanori ^{[1
]}

Ueshima, Koji ^{[1
]}

Sato, Shuichi ^{[1
]}

Sasamata, Masao ^{[1
]}

机构：

[1] Astellas Pharma Inc, Appl Pharmacol Res Labs, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan

来源：

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2013年 / 386卷 / 03期

关键词：

Mirabegron; beta(3)-Adrenoceptor agonist; Overactive bladder; Cerebral infarcted rat; CEREBRAL-ARTERY OCCLUSION; OVERACTIVE BLADDER; DETRUSOR OVERACTIVITY; BETA-3-ADRENOCEPTOR; RELAXATION; EFFICACY; TOLERABILITY; MECHANISMS; SUBTYPES; YM178;

D O I：

10.1007/s00210-012-0821-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat beta-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC50 value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat beta(3)-adrenoceptors. The EC50 values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat beta(1)-adrenoceptors and were sumless and 0.1 for beta(2)-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC50 value of 290 nmol/L. The concentration-response curve of mirabegron was affected neither by the beta(1)-adrenoceptor selective antagonist CGP-20712A nor by the beta(2)-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of beta(3)-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.

引用

页码：247 / 253

页数：7

共 50 条

[31] The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron - a new selective β3agonist [J].

Rechberger, Tomasz ;

Kulik-Rechberger, Beata ;

Miotla, Pawel ;

Wrobel, Andrzej .

GINEKOLOGIA POLSKA, 2014, 85 (03) :214-219

[32] Video-urodynamic effects of mirabegron, a 3-adrenoceptor agonist, in patients with low-compliance bladder [J].

Kamei, Jun ;

Furuta, Akira ;

Akiyama, Yoshiyuki ;

Niimi, Aya ;

Ichihara, Koji ;

Fujimura, Tetsuya ;

Fukuhara, Hiroshi ;

Kume, Haruki ;

Homma, Yukio ;

Igawa, Yasuhiko .

INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (10) :956-961

[33] Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems [J].

Takusagawa, Shin ;

Ushigome, Fumihiko ;

Nemoto, Hiroyuki ;

Takahashi, Yutaka ;

Li, Qun ;

Kerbusch, Virginie ;

Miyashita, Aiji ;

Iwatsubo, Takafumi ;

Usui, Takashi .

MOLECULAR PHARMACEUTICS, 2013, 10 (05) :1783-1794

[34] Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB) [J].

Rossanese, Marta ;

Novara, Giacomo ;

Challacombe, Ben ;

Iannetti, Alessandro ;

Dasgupta, Prokar ;

Ficarra, Vincenzo .

BJU INTERNATIONAL, 2015, 115 (01) :32-40

[35] The β3-adrenoceptor agonist mirabegron increases human atrial force through β1-adrenoceptors: an indirect mechanism? [J].

Mo, Weilan ;

Michel, Martin C. ;

Lee, Xiang Wen ;

Kaumann, Alberto J. ;

Molenaar, Peter .

BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (16) :2706-2715

[36] Mirabegron the first 3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies [J].

Chapple, Christopher .

BJU INTERNATIONAL, 2014, 113 (06) :847-848

[37] Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects [J].

Iitsuka, Hiromi ;

van Gelderen, Marcel ;

Katashima, Masataka ;

Takusagawa, Shin ;

Sawamoto, Taiji .

CLINICAL THERAPEUTICS, 2015, 37 (05) :1031-1044

[38] Is the Addition of CO2 Laser to β3-Adrenoceptor Agonist Mirabegron Effective in the Management of Overactive Bladder? Results of a Randomized Controlled Trial [J].

Kypriotis, Konstantinos ;

Prodromidou, Anastasia ;

Athanasiou, Stavros ;

Zacharakis, Dimitrios ;

Kathopoulis, Nikolaos ;

Douligeris, Athanasios ;

Athanasiou, Veatriki ;

Michala, Lina ;

Grigoriadis, Themos .

MEDICINA-LITHUANIA, 2025, 61 (07)

[39] Efficacy of the β3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials [J].

Chapple, Christopher ;

Khullar, Vik ;

Nitti, Victor W. ;

Frankel, Jeffrey ;

Herschorn, Sender ;

Kaper, Mathilde ;

Blauwet, Mary Beth ;

Siddiqui, Emad .

EUROPEAN UROLOGY, 2015, 67 (01) :11-14

[40] Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome [J].

Igawa, Yasuhiko ;

Michel, Martin C. .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 (03) :177-183

← 1 2 3 4 5 →